Inverse correlation between insulin‐like growth factor binding protein‐I and insulin in patients with acromegaly during treatment with the somatostatin analogue octreotide
- 1 October 1994
- journal article
- clinical trial
- Published by Wiley in Clinical Endocrinology
- Vol. 41 (4) , 495-501
- https://doi.org/10.1111/j.1365-2265.1994.tb02581.x
Abstract
Summary: OBJECTIVE Previous reports have shown an inverse relation between IGFBP‐1 and Insulin levels In healthy men, patients with insulin dependent diabetes mellitus, and insulinoma. We have investigated whether this inverse relation also exists in acromegaly, before and during treatment with octreotide, and whether changes in IGFBP‐1 levels relate to OH and IGF‐I levels.DESIGN We studied short‐term treatment with octreotide in a double‐blind placebo‐controlled 14‐day clinical trial.PATIENTS Eighteen patients with acromegaly were studied.MEASUREMENTS Plasma GH and serum IGFBP‐1 levels were measured at hourly intervals from 0700 to 1800h before randomization (day 0) and on days 4, 6, 8,14 and 20. Serum insulin was determined at 0700, 0800 and 0900 h, and serum IGF‐I at 0700 h.RESULTS Octreotide increased the daily mean IGFBP‐1 level by 43% on day 8 and by 35% on day 14. The IGFBP‐1 levels during octreotide were significantly higher (P < 0·05) compared to placebo, 29·9 ± 3·9 vs 19·9 ± 1·7 μg/l (mean ± SEM) on day 8, and 28·3 ± 3·2 vs 19·.9 ± 1·6 μg/l on day 14. Octreotide treatment significantly suppressed the insulin levels on all observation days by 40–48% compared to placebo. There was a significant inverse correlation between IGFBP‐1 levels and insulin levels, both before treatment and on the last day of treatment (r= 0·79, P= 0·04; r=−0·90, P= 0·02, respectively). GH and IGF‐I were significantly decreased in the octreotide group compared to the placebo group during the entire treatment period. The mean of age related standard deviation scores of IGF‐I In the octreotide group decreased from a pretreatment value of 6·47 ± 0·74 to 3·60 ± 1·20 on day 14. There was no significant correlation between IGFBP‐1 levels and levels of GH and IGF‐I, either before or during treatment.CONCLUSIONS Octreotide treatment, in addition to reducing GH, IGF‐I and insulin levels, is associated with an Increase in IGFBP‐1 concentrations in patients with acromegaly, and it is suggested that the rise in serum IGFBP‐1 Is a consequence of the decrease In insulin secretion.Keywords
This publication has 36 references indexed in Scilit:
- Suppression of endogenous insulin secretion regulates the rapid rise of insulin‐like growth factor binding protein (IGFBP)‐1 levels following acute hypoglycaemiaClinical Endocrinology, 1993
- Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug actionJournal of Clinical Endocrinology & Metabolism, 1992
- Somatostatin analog induces insulin-like growth factor binding protein- 1 (IGFBP-1) expression in human hepatoma cellsEndocrinology, 1992
- Preservation of Inherent Diurnal Serum Insulin-Like Growth Factor Binding Protein 1 Pattern During Low Dose GH InfusionHormone and Metabolic Research, 1992
- Nutrition and somatomedin XXIX. Molecular regulation of IGFBP-1 in hepatocyte primary cultureDiabetes, 1992
- Insulin secretion and insulin-like growth factor-I levels in active and controlled acromegalyClinical Endocrinology, 1992
- Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6)Progress in Growth Factor Research, 1991
- IGFBP-1, an insulin like growth factor binding protein, is a cell growth inhibitorBiochemical and Biophysical Research Communications, 1991
- Insulin‐Like Growth Factor (IGF) Binding Proteins: the Role of Serum IGFBPs in Regulating IGF AvailabilityActa Paediatrica, 1991
- Lack of growth hormone effect on insulin-associated suppression of insulinlike growth factor binding protein 1 in humansDiabetes, 1990